Patients of age ≥ 2 years are eligible for the study
Lansky or Karnofsky performance status ≥ 70
Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
Willing to provide blood samples for correlative research purposes
Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is \>= 8 cm
You may not be if
Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
* Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
Any of the following:
* Pregnant patients
* Nursing patients
Clareo Health | Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
